590 filings
Page 3 of 30
DEFA14A
qrm1nzwe
29 Sep 22
Additional proxy soliciting materials
4:16pm
8-K
kibd2n3tvi62 5314
29 Sep 22
Other Events
4:15pm
8-K
xh87ovw5n
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
0vfh 2w2kkuztlakvl
15 Aug 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
7:03am
8-K
ha3rgqsk
10 Aug 22
Other Events
12:00am
EFFECT
o1pa87nil qu6mqrzq
5 Aug 22
Notice of effectiveness
12:15am
424B3
xiy4 ijx81yctolu8rx0
4 Aug 22
Prospectus supplement
4:17pm
CORRESP
w2y9jutx9bwl970l
2 Aug 22
Correspondence with SEC
12:00am
UPLOAD
cxfc4 xjrpx0mb0
1 Aug 22
Letter from SEC
12:00am
4/A
tlou4bif
22 Jul 22
9 METERS BIOPHARMA / Mark A Sirgo ownership change
4:21pm
SC 13G
if29km 7r3yugp2b5e
8 Jul 22
9 METERS BIOPHARMA / BlackRock ownership change
4:57pm
4
jkuytwi ittc
8 Jul 22
9 METERS BIOPHARMA / John Temperato ownership change
8:01am
4
40vc pwlwiuqhs9b5p
6 Jul 22
9 METERS BIOPHARMA / Mark A Sirgo ownership change
4:43pm
SC 13D/A
k614bzj9i
1 Jul 22
9 METERS BIOPHARMA / OrbiMed Israel BioFund GP Limited Partnership ownership change
5:20pm
8-K
4j20p
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
c565tidm39 up
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am